CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 51 enrolled
Drug / intervention
LEO 19123 Cream (calcipotriol plus LEO 80122) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00764751
NCT00764751Phase 2Completed
CompareCT.gov

LEO 19123 Cream in the Treatment of Psoriasis Vulgaris

LEO Pharma·interventional·Posted Oct 2, 2008·Updated Mar 7, 2025

In Brief

A Phase 2 clinical trial evaluating LEO 19123 Cream (calcipotriol plus LEO 80122), Dovonex® cream, and 1 other intervention for Psoriasis Vulgaris. Completed, enrolled 51 participants across 1 site.

Detailed Summary

This study will compare the efficacy and safety of once daily treatment of LEO 19123 cream versus Dovonex® cream (applied twice daily) and versus LEO 19123 cream vehicle alone (applied twice daily) in subjects with psoriasis vulgaris. Subject will be treated for 4 weeks. All subjects will apply LEO 19123 cream to psoriasis lesions on the left or right side of the body and either Dovonex® cream or cream vehicle to lesions on the other side.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesCanada
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2, 2008
Enrollment StartSep 1, 2008
Primary CompletionDec 1, 2008
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.8 years ago

Interventions

LEO 19123 Cream (calcipotriol plus LEO 80122)drug

Once daily application

Dovonex® creamdrug

Twice daily application

Cream vehicledrug

Twice daily application